Docetaxel - BlueLink Pharmaceuticals

Drug Profile

Docetaxel - BlueLink Pharmaceuticals

Alternative Names: CRLX-301; Docetaxel nanoparticle - Cerulean Pharma

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cerulean Pharma
  • Developer BlueLink Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 21 Dec 2017 NewLink Genetics Corporation terminates a phase-I/II clinical trial due to lack of funding in Solid tumours (Late-stage disease; Refractory metastatic disease) in Australia (IV) (NCT02380677)
  • 20 Mar 2017 Cerulean enter into an agreement with BlueLink Pharmaceuticals to sell camptothecin (CRLX 101) and docetaxel (CRLX 301)
  • 04 Aug 2016 Phase-II clinical trials in Solid tumours (Late-stage disease, Refractory metastatic disease) in USA, Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top